Lonza has published a guide to clinical-grade induced pluripotent stem cell (IPSC) manufacture, addressing concerns around the derivation of cellular materials.
Investments in technologies and capabilities are reaping rewards says Catalent which will continue placing “disproportionate emphasis” on its biologics business.
Boehringer Ingelheim has licensed a microbial expression technology from Vectron Biosolutions for use with its own molecules and for customers through its CMO business.
Phage manufacturers are yet to take advantage of single-use techs says Cellexus, which hopes bioreactors employing its ‘air lift’ system will win it customers in this emerging niche.
Specialist manufacturer Cellular Therapeutics has been awarded a contract from the UK Cell Therapy Catapult to produce a new cell-based cancer therapy.
French biotech TxCell is outsourcing manufacture of its T-cell therapy Ovasave to MaSTherCell, and says it expects to regain GMP certification of its own site later this year.
Roche is expanding its manufacturing operations to service its biologics pipeline, but the firm says it will continue to outsource approximately 20% of all production.
Small-scale production techs will dominate biopharma says the UK organisation tasked with developing the £20m “biologics factory of the future” and the £38m National Biologics Manufacturing Centre in Darlington.
EMA guidance on process validation for drugmakers is the latest update in cGMP regulations to manage a pharma world shifting from chemical to biological processing, says NNE Pharmaplan.
Small biotechs are turning to single-use to retain ownership of their manufacturing processes, says Merck Millipore as industry predicts continued double-digit growth for such systems.
Merck Millipore has entered an agreement whereby it will control and manage the Singulex Life Science Research business, which offers a technology that can provide ultra-sensitive protein detection.
Biomay has licensed a yeast-based expression system from fellow Austrian biotech VTU Technologies to use for the commercial production of its recombinant allergens.
Danaher's acquisition of Pall will not change the competitive landscape in the bioprocessing tech industry says Thermo Fisher, as it earmarks $10bn for further M&A activity.
Alexion will expand its manufacturing network with a €450m ($507m) biologics facility in Ireland, a week after entering an $8.4bn agreement to acquire Synageva.
The acquisition of Pall Corporation by either Thermo Fisher or Danaher could spur further M&A in the life science tech industry, according to an analyst.
WuXi PharmaTech subsidiary WuXi Biologics has begun construction on a new $150m biologics manufacturing facility in Wuxi, China, which is expected to be the largest mammalian cell culture manufacturing sire using disposable bioreactors in the world.
The plant of the future will be increasingly equipped with disposable technology but single-use will never fully replace stainless steel, according to biomanufacturers at a recent industry event.
Cheaper disposable manufacturing techs and increased demand for outsourced production will see more CMOs enter the contracting sector according to HighTech Business Decisions
The world’s top pharma and biologics manufacturing and processing companies have come together in New York this week to showcase the latest in equipment and services.
San Antonio, Texas-based StemBioSys has closed an $8m round of Series A preferred stock financing that it will use to help launch its bone marrow-High Performance MicroEnvironment (BM-HPME) stem cell culture system.
